AS-1409

N/A

Report date: 2022/11/25 17:28:41

Base Information

Drug NameAS-1409
Drug Alias NameTumour-targeting antibody BC1/IL-12 fusion drughuBC1/IL-12 fusion proteinAntibody-cytokine fusion drug (AS1409)huBC1/IL12 fusion drugBC1-IL-12 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterferon gamma stimulantsInterleukin-12 receptor stimulants
TargetsInterferon gammaInterleukin-12 receptor
Therapy Area/IndicationsCarcinoma, Renal CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAntisomaEmd Lexigen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAntisoma Research Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal CellMelanoma

Other Information

ATC CodeN/A
Related LinksDrugBank